![]() Muller continued, âWith this acquisition, Avedro now has the largest installed base of cross-linking devices in the world to drive its single dose riboflavin revenue. We look forward to immediately increasing our MedioCROSS riboflavin revenue through access to the established base of UV-X users and to further increasing device and riboflavin revenue by expanding sales of UV-X devices in all the markets we serve.â Dr. Michael Mrochen, IROC Innocross has firmly established the value of its UV-X devices. Under the direction of its founder, Prof. Our expanded portfolio of devices and riboflavin brands gives Avedro an unmatched product offering across the entire corneal cross-linking market worldwide.ĭavid Muller, PhD, CEO of Avedro commented, âI am extremely pleased to have completed this important acquisition for Avedro. With this acquisition, Avedroâs platform of cross-linking technology now spans the entire spectrum of corneal cross-linking procedures, from treating corneal pathology with our UV-X devices and MedioCROSS riboflavinâto enhancing LASIK outcomes with our KXL System and VibeX riboflavinâto developing non-invasive refractive procedures with our advanced KXL II System. To date, IROC Innocross has sold its UV-X devices to more than 1,000 ophthalmologists giving it the largest installed base of cross linking devices in the world. IROC Innocross was the first company to commercialize a cross-linking device for the treatment of keratoconus and other corneal pathologies. ![]() Avedro Inc., a Boston-based ophthalmic medical device and pharmaceutical company announces today that it has purchased the assets of IROC Innocross AG, of Zug, Switzerland.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |